Perrigo's infant formula deal includes $40 million at closing; up to $135 million depends on future milestones.
Perrigo (PRGO) will sell its infant formula business to MeridianMade for up to $135 million, with $40 million at closing. The deal, expected to close in early 2027, aims to streamline Perrigo's portfolio, improve margins, and reduce future capital expenditures. Perrigo will record a non-cash impairment charge in Q4 2026.
How this was made
The 30-second read
Why it matters
The transaction is expected to simplify reported results by moving Infant Formula into discontinued operations starting Q4 2026, while Perrigo anticipates a non-cash impairment charge in Q4 2026 and uses net proceeds per its capital allocation priorities.
Market read
Traders should weigh deal economics ($40 million closing plus up to $135 million milestones), the probability of milestone achievement, and the near-term accounting impacts (Q4 2026 impairment and discontinued-ops reclassification).
What to watch
The planned non-cash impairment in Q4 2026 could drive earnings volatility and investor skepticism about the underlying asset’s economics, even if cash impact is limited.
Background
Perrigo is executing its Three-S plan (Stabilize, Streamline, Strengthen) and this agreement follows a strategic alternatives review for its Infant Formula business.
Ticker impact
Perrigo agreed to divest its infant formula business to MeridianMade for $40 million at closing, with up to $135 million in milestones and a 2026 impairment charge.
Likely near-term valuation sensitivity to the $40 million closing value versus the probability-weighted $135 million milestones, plus margin and capex implications.
The article discloses deal structure, expected closing in H1 2027, and a planned non-cash impairment charge in Q4 2026, all of which can affect forward earnings optics and risk perception.
Market effects
Highlights ongoing consolidation and portfolio reshaping in consumer self-care and infant nutrition manufacturing, potentially affecting competitive dynamics for store-brand formula supply.
Emphasizes domestic manufacturing infrastructure for infant-grade formula, which may influence perceptions of supply-chain resilience in the US.
Limited direct global read-through beyond investor sentiment toward consumer healthcare divestitures and manufacturing outsourcing.
Counterpoint
The headline proceeds are milestone-dependent, so the market may discount the upside and focus on execution and regulatory approval risk rather than the stated margin/capex benefits.
Key entities
- companyPerrigo Company plc
US-listed consumer self-care and OTC health products company announcing the divestiture of its Infant Formula business.
- companyMeridianMade
Infant-focused nutrition manufacturer and contract services provider acquiring Perrigo’s Infant Formula business.
